Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 5;101(1):adv00362.
doi: 10.2340/00015555-3709.

Avapritinib for Cutaneous Mastocytosis

Hannah Lee  1 , Tian Li, Joshua Wisell, Jeffrey Schowinsky, William A Robinson
Affiliations

Avapritinib for Cutaneous Mastocytosis

Hannah Lee et al. Acta Derm Venereol. .
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Skin photographs of initial presentation and post-treatment with avapritinib. (A) Initial presentation of telangiectatic, erythematous macules on bilateral thighs. (B) Resolved telangiectatic, erythematous macules on bilateral thighs after avapritinib. (C) Telangiectatic, erythematous macules progressed to whole body including abdomen. (D) Resolved telangiectatic, erythematous macules on abdomen after avapritinib.
Fig. 2
Fig. 2
Pathology of skin and bone marrow pre- and post-treatment with avapritinib. (A) Skin biopsy with increased number of mast cells in a perivascular and interstitial distribution associated with superficial telangiectasias, consistent with telangiectasia macularis eruptiva perstans (H&E stain, 12.6x magnification). (B) Skin biopsy after avapritinib without atypical population of mast cells (H&E stain, 12.6x magnification). (C) Bone marrow biopsy revealing hypercellular marrow of > 90% cellularity with 10–20% CD117- and CD25-positive atypical mast cells within nodules consistent with systemic mastocytosis (H&E, 12.6x magnification). (D) Bone marrow biopsy after BLU-285 with normocellular marrow negative for increased mast cells. (H&E, 12.6x magnification).
Fig. 3
Fig. 3
Serum tryptase level during treatment. Note the downtrend after start of avapritinib and again with the increased dose of avapritinib.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Erben P, Schwaab J, Metzgeroth G, Horny HP, Jawhar M, Sotlar K, et al. . The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 2014; 93: 81–88. - PubMed
    1. Severino M, Chandesris MO, Barete S, Tournier E, Sans B, Laurent C, et al. . Telangiectasia macularis eruptiva perstans (TMEP): A form of cutaneous mastocytosis with potential systemic involvement. J Am Acad Dermatol 2016; 74: 885–891 e881. - PubMed
    1. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood 2017; 129: 1420–1427. - PMC - PubMed
    1. Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, et al. . A precision therapy against cancers driven by KIT/PDGFRA mutations. Sci Transl Med 2017; 9: eaao1690. - PubMed
    1. Drummond MW, DeAngelo DJ, Deininger MW, Radia D, Quiery AT, Hexner EO, et al. . Preliminary safety and clinical activity in a Phase 1 study of Blu-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (SM). Blood 2016; 128: 477–477.

LinkOut - more resources